… , REGEN-COV, a combination of the monoclonal antibodies casirivimab … REGEN-COV
has activity in vitro against current severe acute respiratory syndrome coronavirus 2 (SARS-CoV…

… evaluate whether subcutaneously administered REGEN-COV could be used … CoV-2. We
used a household-contact trial design to assess whether REGEN-COV could prevent SARS-CoV…

… Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab antibody
combination (REGEN-COV) to prevent progression from early asymptomatic SARS-CoV-2 …

… ysis on the spike RBD, where the REGEN-COV antibodies are known to bind and where
all previously identified resistant variants to either antibody are located. Analysis of the RBD …

… REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has
been approved as a treatment for high-risk patients infected with SARS-CoV… of REGEN-COV …

… to patients who were serum antibody-negative and had these … of REGEN-COV, regardless
of baseline serum antibody status… combinations of non-competing antibodies, such as REGEN-…

… 7 was significantly greater in the REGEN-COV combined 2400mg+8000mg group versus …
serum antibody–negative patients and in the overall population, respectively. REGEN-COV …

… heard of REGENCOV and … REGEN-COV were seen to have a lower all-cause hospitalization
compared to bamlanivimab at day 28. Is REGEN-COV the holy grail of monoclonal antibody …

… According to our local treatment protocol, anti-SARS-CoV-2 neutralizing antibody cocktails
… anti-CD20 antibodies, our local protocol allows treatment with REGEN-COV after more than …

… Green dashed line: cumulative number of REGEN-Cov administrations. Red line: cumulative
number of COVID-19 infections among patients treated with REGEN-Cov in our cohort. …